WALTHAM,
Mass., Nov. 11, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
clinical-stage biotechnology company utilizing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches to target improved efficacy and
convenience in the treatment of inflammatory bowel disease ("IBD"),
today announced it will report interim results from the Phase 1
SPY001 healthy volunteer trial on Tuesday,
November 12, 2024. Following the announcement, the Company
will host a conference call and webcast at 8:00am ET to discuss the results.
To access the live and archived webcast, please visit the
Investor Relations page of Spyre's website
at https://ir.spyre.com/events-and-presentations. The archived
webcast will be available for a limited time on the Company's
website.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation of inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes investigational extended
half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please
visit http://spyre.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-from-phase-1-healthy-volunteer-trial-for-spy001-its-novel-half-life-extended-anti-47-antibody-for-the-treatment-for-inflammatory-bowel-disease-on--302301674.html
SOURCE Spyre Therapeutics, Inc.